Response in germination and seedling growth in Phaseolus mungo under salt and drought stress.

The effect of salt and drought stress at the water potentials of -2, -4,-6 and -8 bars induced by NaCl and PEG 6000 (Polyethylene glycol 6000) each, on germination and early seedling growth, were investigated for two varieties (PU-19 and Type-9). Electrical conductivity (EC) value of the NaCl solutions were 4.5, 8.8, 12.7 and 16.3 dS m-1. Germination percentage, root and shoot length, and seedling fresh and dry weight were measured in the study. The objective was to determine genotypic differences among P.mungo varieties in terms of salt and drought stress and to determine factors(salt toxicity or osmotic stress due to PEG) inhibiting seed germination. The germination results revealed that the genotypes significantly differed for salt and drought stress. PU-19 appeared to be more tolerant to salt and drought stress comparable to var. Type-9. Both NaCl and PEG inhibited germination and seedling growth in both the varieties, but the effects of NaCl compared to PEG was less on germination and seedling growth. All varieties were able to germinate at all NaCl levels without significant decrease in germination, while a drastic decrease in germination was recorded at -6 and -8 bars of PEG. It was concluded that inhibition in germination at equivalent water potential of NaCl and PEG was mainly due to an osmotic effect rather than salt toxicity.

Management of HCV infection: Current issues and future options.

Hepatitis C virus (HCV) is a common cause of chronic liver disease (CLD). Presently the standard regime comprises a combination of PEG-IFN and ribavirin. Sustained virologic response (SVR) is defined as the absence of HCV RNA in the serum six months after the end of treatment . With standard treatment, in patients with genotype1 infections, SVR lies between 42% to 56%, whereas for genotypes 2 and 3 the SVR is from 76% to 82%. Thus, a large percentage of patients fail to achieve SVR even with improvised standard treatment. Such patients may be divided initially into relapsers and nonresponders. The decision to re-treat should be based on the presence of clinical, virological and histological factors that predict the possibility of successful outcome with further therapy. Both the type of previous therapy and previous response are very important factors in guiding re-treatment. The development of new therapeutic agents is critical for further improvement in the management of chronic hepatitis C as current therapeutic options have rather low efficacy in certain subgroups, such as those with HCV genotype 1 or patients with advanced liver disease, and most probably in nonresponders and relapsers. Moreover, pegylated IFNa and/or ribavirin are associated with frequent side effects and have a negative impact on the patient’s quality of life. Therefore, the development of new effective and safe drugs is a matter of significant clinical importance.